NL-OMON27023招募中不适用
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
ErasmusMC, Rotterdam0 个研究点目标入组 156 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- 未提供
排除标准
- •Isolated extramedullary relapse
- •Patients with isolated extramedullary disease are excluded (not applicable to lymphoma patients except for isolated CNS-relapse)
研究者
相似试验
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in children with relapsed/refractory acute lymphatic leukemia (ALL)pediatric CD22-positive relapsed/refractory Acute Lymphoblastic LeukemiaMedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000012975EUCTR2016-000227-71-ESErasmus Medical Center96
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in children with relapsed/refractory acute lymphatic leukemia (ALL)EUCTR2016-000227-71-FIErasmus Medical Center156
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in children with relapsed/refractory acute lymphatic leukemia (ALL)EUCTR2016-000227-71-NLErasmus Medical Center156
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in children with relapsed/refractory acute lymphatic leukemia (ALL)pediatric CD22-positive relapsed/refractory Acute Lymphoblastic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2016-000227-71-DEErasmus Medical Center156
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in children with relapsed/refractory acute lymphatic leukemia (ALL)pediatric CD22-positive relapsed/refractory Acute Lymphoblastic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2016-000227-71-NOErasmus Medical Center156